**1. Introduction**

296 Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice

Torzewski, J., Torzewski, M., Bowyer, DE., Fröhlich, M., Koenig, W., Waltenberger, J.,

Tzanatos, HA., Tseke, PP., Pipili, C., Retsa, K., Skoutelis, G., & Grapsa, E. (2009).

Vigushin, DM., Pepys, MB., Hawkins, PN.(1993). Metabolic and scintigraphic studies of

Vraetz, T., Ittel, TH., Mackelenbergh, MG., Heinrich, PC., Sieberth, HG., & Graeve, L. (1999).

Wallen, MD., Radhakrishnan, J., Appel, G., Hodgson, ME., & Pablos-Mendez, A. (2001). An

Xie, J., Yi Q. (2003). Beta 2 microglobulin as a potential initiator of inflammatory responses.

Yeun, JY., Kaysen GA. (2000). C-reactive protein, oxidative stres, homocysteine, and troponin

Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999). İnflammation

Zumrutdal, AO., Bakner, O., Ucan, H., Atalay, HV., & Bodur, H. (2000). Relationship

Zumrutdal, A., Sezer, S., Demircan. S., Seydaoglu. G., Ozdemir, FN, & Haberal, M. (2005).

Zumrutdal, A., Demircan, S., Seydaoglu, G., Singan, M., Sezer, S., Ozdemir, FN., & Haberal,

Zumrutdal, A., Baltali, M., Micozkadioglu, H., Torun, D., Sezer, S., Ozdemir, FN. & Haberal

*in Nephrology and Hypertension*. Vol. 9, No:6, pp.621-630, ISSN1062-4821 Ylmaz, R. Altun, B., Ozer, N., Hazirolan, T.,& Turgan, C. (2010). Impact of cytokine

*Trends in Immunology*. Vol. 24, No:5, pp. 228-229, ISSN1471-4906

*International Suppl*. Vol. 55, No:2, pp. 648-658, ISSN 0098-6577

*Failure*. Vol.32, No:7, pp.806-816, ISSN0886-022X.

86, No:4, pp. 522-523, ISSN0028-2766

ISSN 1320-5358

ISSN 1320-5358

ISSN0886-022X

study. *Renal Failure*. Vol. 31, No:2, pp.91-97, ISSN0886-022X

*Clinical Investigation.* Vol. 91, No:4, pp. 1351-1357, ISSN 0021-9738

No:9, pp.1386-1392,ISSN 1079-5642

pp.2137-2143, 0931-0509

7322

Fitzsimmons, C. et al. (1998). C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries*. Arteriosclerosis, Thrombosis, and Vascular Biology.* Vol. 18,

Cardiovascular risk factors in non-diabetic hemodialysis patients: a comparative

radioiodinated human C- reactive protein in health and disease. *The Journal of* 

Regulation of beta 2 microglobulin expression in different human cell lines by proinflammatory cytokines. *Nephrology Dialysis and Transplantation*. Vol.14, no:9,

analysis of cardiac mortality in patients with new-onset end stage renal disease in New York state. *Clinical Nephrology*. Vol. 55, No.2, pp.101-108, ISSN0301-0430 Wilson, AM., Kimura, E., Harada, RK., Nair, N., Narasimhan, B, Meng, XY., Zhang, F., et al.

(2007). Beta 2 microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. *Circulation*. Vol.116, No: 12, pp.1396-1403, ISSN0009-

as inflammatory and metabolic predictors of atherosclerosis in ESRD*. Current Opinion* 

genotype on cardiovascular surrogate markers in hemodialysis patients. *Renal* 

enhances cardiovascular risk and mortality in hemodialysis patients. *Kidney* 

between uremic myopathy and false-positive cardiac troponin T test. *Nephron*. Vol.

Cardiac troponin I and beta 2 microglobulin as risk factors for early- onset atherosclerosis in patients on haemodialysis. *Nephrology*. Vol. 10, No:5, pp. 453-458,

M. (2006). Atherosclerosis in haemodialysis patients without significant comorbidities: Determinants of progression. *Nephrology*. Vol. 11, No:6, pp 489-493,

M. (2007). Determinants of coronary artery disease in nondiabetic hemodialysis patients: A matched case-control study. *Renal Failure*. Vol. 29, No:1, pp.67-71, Reverse epidemiology, or risk factor paradox, has been used to describe the observed effect that traditional risk factors for cardiovascular disease may not necessarily signify the same risk for hemodialysis patients (HP) as for healthy populations. In fact, recent published findings have suggested counter-intuitive outcomes (Chavalitdhamrong, Danovitch, & Bunnapradist, 2007; Tsirpanlis et al., 2009) regarding the role cholesterol may play in disease progression in HP with chronic inflammation and malnutrition comorbidities (Dungan, Guster, DeWalt, & Buse, 2007). However, contemporary experimental studies regarding reverse epidemiology are lacking. The few published findings on this topic suggest chronic inflammation, as measured by C-reactive protein (CRP), and malnutrition, as measured by albumin, is associated with normal cholesterol levels yet higher levels of mortality (Chavalitdhamrong, et al., 2007; Chmielewski, Carrero, Nordfors, Lindholm, & Stenvinkel, 2008).

In contrast, traditional risk factors such dyslipidemia, hyperhomocysteinemia, obesity, or hypertension may provide protective effects in HP, at least in the short term (Kalantar-Zadeh, Block, Humphreys, & Kopple, 2003). Important predictors of clinical outcomes in HP are protein-energy wasting (malnutrition) (PEM) and inflammation (Fleischmann, Bower, & Salahudeen, 2001; Kalantar-Zadeh & Kopple, 2001; Kopple, 1997; Kopple, Zhu, Lew, & Lowrie, 1999; Lowrie & Lew, 1990; Nishizawa, Shoji, Ishimura, Inaba, & Morii, 2001). Because inflammation and PEM are interconnected and similarly affect markers of nutritional status both are considered part of a malnutrition inflammation complex (MIC) (Kalantar-Zadeh, et al., 2003; Kalantar-Zadeh & Kopple, 2001; Kalantar-Zadeh, Kopple, Block, & Humphreys, 2001). Thus, this chapter will address inflammation, malnutrition, cholesterol, and the overall concept of reverse epidemiology in HP relative to MIC as well as the implications of this information on short- and long-term treatment.
